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Abstract
Background:  Patient-reported side effect questionnaires offer a simple method for the systematic
measurement of drug-related side effects. In order to measure patients' inhaled corticosteroids (ICS)
related side effect perceptions the 14-day retrospective Inhaled Corticosteroid Questionnaire (ICQ) was
developed. In this research we aim to assess the construct validity and reliability of the ICQ and test its
responsiveness to dose changes in adult asthma patients.
Methods: In a cross-sectional study, current inhaler users with asthma completed the ICQ (27 with non
ICS inhaler; 61 BDP equivalent daily ICS low dose ≤400 µg; 62 mid dose 401–800 µg; and 105 with high
dose >800 µg). We generated 3 construct validity hypotheses: 1) a hierarchical dose-response pattern for
scoring of the individual items on the ICQ, and statistically significant differences in the scores of each of
the 15 ICQ domains by ICS dose group 2) an association between ICS dose and ICQ scoring after adjusting
for appropriate confounders in multiple regression; 3) greater convergence between local side effect
domains than between systemic and local domains of the scale. Test-retest reliability was assessed on a
randomly selected subgroup of patients (n = 73) who also completed the ICQ a second time after 7 days.
In a separate longitudinal study, 61 patients with asthma completed the ICQ at baseline and after changing
their daily ICS dose, at 2- and 6- months, in order to test the ICQ's responsiveness.
Results: All three construct validity hypotheses were well supported: 1) a statistically significant difference
existed in scores for 14 domains, the high ICS dose group scoring highest; 2) ICS dose independently
predicted ICQ scoring after adjusting for confounders; 3) greater convergence existed between local ICQ
domains than between local and systemic domains. The ICQ had good reproducibility: test-retest
intraclass correlation coefficients were ≥0.69 for all but the 'Facial Oedema' domain. In the longitudinal
study, ICQ scores for 'Voice Problems' changed significantly at 2- and 6-months from baseline and other
ICQ domains displayed trends in scoring change accordant with dose modulation at 6-months.
Conclusion: The ICQ has good dose-related discriminative properties, is valid, reliable, and shows
potential responsiveness to ICS dose change.
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Background
Drug side effects are of considerable concern to patients
[1,2]. Inhaled corticosteroids (ICS), which are effective
and widely recommended for controlling airway inflam-
mation in asthma, are also known to cause many local
and systemic side effects [3-6]. A crucial chasm may exist
between doctors and patients with respect to their
approach to drug side effects. On the one hand, doctors
may avoid discussing patients' aversions to prescribed
medicines [7], and on the other hand patients independ-
ently modify their treatment regimes due to concerns
about potential or perceived side effects without inform-
ing their doctor [1,8]. It is perhaps unsurprising then, that
drug side effects are associated with non-compliance to
prescribed medication regimes in asthma [9-12], and to
poor asthma outcomes [13,14].
Patient-centered self-report questionnaires need to be
properly developed, validated and widely used to permit
the measurement of patient-perceived side effects in the
context of real-life practice, clinical trials and other
research. These instruments may also provide a systematic
method for the exploration of associations between side
effect perceptions and medication taking behavior or
other important health-related outcomes. Few drug side
effect questionnaires exist, probably due to the lack of a
clearly defined methodology for the development of such
complex instruments. Those that are frequently cited are
predominantly used for the measurement of psychoactive
drug side effects (Udvalg for Klinische Undersøgelser
(UKU)[15,16], Liverpool University Neuroleptic Side
Effect Rating Scale [17]) and many still require further val-
idation work.
We developed the Inhaled Corticosteroid Questionnaire
(ICQ) using a combination of well-established methods
from the fields of health status and psychological assess-
ment scale development [18],.{Ghiselli, 1981 420/id},
[20]. In our previous work we used qualitative methods to
generate the 57 side effect items included in the 15
domains of the ICQ (table 2), and in subsequent cross-
sectional testing we demonstrated the face validity of the
scale in 395 inhaler users [3]. The ICQ covers a range of
patient-perceived side effects including voice, throat, skin
and mood problems. The questionnaire then underwent
linguistic validation for translation into 19 languages (car-
ried out by Mapi France), with international harmoniza-
tion resulting in some minor changes to the wording of
the original English version (current questionnaire on our
website [21]). The aims of the two studies presented in
this current paper are four-fold. In the first study we
empirically construct the domains of the ICQ, and test the
construct validity and reliability of the full ICQ and
respective domains. In the second study we examine the
responsiveness of the questionnaire to change in ICS
dose.
Methods
Study 1 – Domain construction, construct validity and 
reliability of the ICQ
Ethical approval was not required for this study which
required only questionnaire completion.
Patients
Contactable patients from 3 existing North Netherlands
asthma cohorts, with a physician diagnosis of asthma and
hyperresponsive to histamine (30 seconds method; PC20
< 32 mg/ml) were invited to participate in the study.
Included patients were consenting current inhaler users,
aged 16 to 74 years, with <20 pack years. Excluded
patients used >1 course of oral steroids in the past 3
months and/or any oral steroid use 4 weeks prior to study,
a steroid injection in the previous 6 months or any change
in their ICS regimen in the previous 14 days.
Before analysis participants were divided into four groups
based on their daily ICS dosage: non ICS inhaler, low dose
ICS (≤400 µg), mid dose ICS (401–800 µg), high dose ICS
(>800 µg)[22]. All stated ICS doses are BDP equivalent
where 1 µg of beclomethasone dipropionate/budesonide
is equivalent to 0.5 µg fluticasone propionate irrespective
of delivery device used [23,24].
Study questionnaire
Patients each completed an identical self-report question-
naire at home, which elicited data on:
1. Medication use: daily use of inhaled asthma medica-
tion (ICS, Short-acting β2-agonist (SABA), long-acting β2-
agonist (LABA)); current use of other steroid medication
(oral tablet, nasal, ocular, dermal, eye, ear drops or
creams); prednisone courses in previous three years; ster-
oid injections in previous 6-months; current use of addi-
tional prescribed medications.
2. Inhaler behavior: spacer use; post-inhalation mouth
rinsing.
3. Date of starting ICS.
4. Perceived ICS side effect: Inhaled Corticosteroid Ques-
tionnaire (ICQ).
5. Asthma severity and history: 6-item Asthma Control
Questionnaire (ACQ) scored 0–6 (Forced expiratory vol-
ume in one second, question omitted)[25]; number of
emergency GP appointments for asthma in the last year;
age asthma diagnosed.Respiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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Table 1: Patient characteristics and demographics by ICS daily dose group
Variable Total Sample Non ICS Inhaler Low dose ICS 
≤400 µg
Mid dose ICS
401–800 µg
High dose ICS
> 800 µg
p-value
n = 255 n = 27 n = 61 n = 62 n = 105
Age (years) 42 (33–50) 33 (28–39) 40 (32–51) 47 (37–50) 42 (33–50) 0.005
% male 44 44 51 44 40 0.295*
Smoking
% current or past smokers 44 37 44 47 43 0.775*
Pack yearsa 0 (0–3) 0 (0–2) 0 (0–4) 0 (0–4) 0 (0–2) 0.782
Asthma severity
Asthma control questionnaire (ACQ) score (0–6) 0.8 (0.3–1.5) 1.2 (0.5–1.7) 0.5 (0.2–1.3) 0.7 (0.3–1.2) 0.8 (0.3–1.7) 0.075
No. emergency GP appointments for asthma in last 
year % none/% ≥1
80/20 85/15 87/13 84/16 73/27 0.034
Educational level achieved
% Primary and lower vocational 34 26 31 34 37
% Secondary/intermediate vocational 38 33 33 47 37
% Higher vocational/university 28 41 36 19 26 0.070
Use of asthma medication
No. of daily puffs SABA % none/% 1–2/% ≥3 69/24/7 22/59/19 79/20/1 84/10/6 68/25/7 0.049¶
Daily equivalent dose† of LABAc %0 µg/%1–200 µg 39/61 89/11 53/47 33/67 20/80 ≤0.001
No. of courses of Prednisolone in last 3 yearsc % 
none/%1–2/%≥3
57/27/16 74/19/7 64/27/9 58/27/15 49/29/22 0.002¶
% currently using nasal steroids 25 7 28 31 25 0.296*
% currently using dermal or ocular steroids 6 7 10 2 5 0.291*¶
No. of other concomitantly prescribed medications % 
none/%1–2/%≥3
37/42/21 52/30/18 39/48/13 34/48/18 34/39/27 0.048
Perceived side effect in last 14-days:
ICQ total score 11 (4–22) 5 (0.8–11) 7 (3–14) 10 (3–21) 15 (9–30) ≤0.001
Personality:
Negative affectivity score (PANAS) 17 (14–22) 14 (13–20) 15 (13–21) 17 (14–21) 17 (15–24) 0.09
Neuroticism score (EPQ-RSS) score (0–12)d 4 (2–7) 4 (1–7) 3 (1–6) 4 (2–6) 4 (1–7) 0.727*
Inhaler behavior
% rinsing mouth after inhalatione 75 82 77 0.928*
% using spacer device 2 7 15 0.003
% use of ICS 7 days per week (adherent)b 82 90 99 ≤0.001
*Variable entered into regression due to potential confounding indicated by research literature
Variable not entered into regression as avariable 'current or past smokers' entered into model bvariable used to calculate µg daily ICS dose
Missing data: cn = 7, dn = 2, en = 1
†Salmeterol equivalent dose: 4 µg salmeterol = 1 µg formoterol (only 4% of total sample used >100 µg daily)
All variables % or median (IQR), tested with Chi-square (p-value linear trend) or Kruskal-Wallis except ¶ Fishers Exact Test (p-value linear trend)Respiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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Table 2: The 15 domains and 57 items of the ICQ scale.
Voice Problems – 15 items: Mood Problems – 3 items:
• hoarseness of the voice • feeling 'grumpy'
• a 'rough' voice • mood swings
• a noticeable change to your voice • feeling 'easily irritated'
• your voice feeling similar to how your voice feels when recovering 
from the flu
• your voice feeling like it had 'gone to the back of your throat' Taste Disruption – 3 items:
• not being able to sing • a change in your ability to taste
• loss of speech volume so that you couldn't talk as loudly as normal • a loss of ability to taste
• a feeling of exhaustion when talking • a loss of appetite
• a painful throat when talking
• a feeling that other people couldn't understand your speech because 
you speak too softly or not clearly enough
Perspiration – 2 items:
• a breaking voice • sweating
• a 'rough' throat • sweating during the night
• a sore throat
• an unpleasant feeling in your throat Oropharyngeal Itching – 2 items:
• a dry throat • an itchy feeling on the roof of your mouth
• an itchy feeling in the back of your throat
Oropharynx Problems – 9 items:
• coughing Thirst – 2 items:
• coughing up phlegm • feeling thirsty
• coughing up thick mucus • wanting to drink liquid (because of a dry mouth)
• thick mucus coming up
• thick mucus sticking at the back of your throat Tiredness – 2 items:
• a need to clear your throat • difficulty sleeping
• mucus in your throat • feeling tired
• a 'clump' in your throat
• a feeling that 'a layer of mucus stays on the back' of your throat Oral Candidiasis – 1 item:
• oral thrush (fungal infection: sore throat covered with pustules, and 
difficulty swallowing)
Unpleasant Taste – 7 items:
• a terrible taste in your mouth Facial Oedema – 1 item:
• a 'taste' on the teeth • a swollen face or fluid around the face
• a 'bad taste' or unfresh feeling in your mouth
• bad breath Vision Deterioration – 1 item:
• wanting to rinse your mouth • some kind of deterioration of your vision
• wanting to brush your teeth
• wanting to chew gum Dental Deterioration – 1 item:
• any form of dental decline (tooth decay, tooth staining etc.)
Skin, Hair and Nails – 7 items:
• dry skin Eye Dryness – 1 item:
• dry skin on the face • dry eyes
• bruising easily
• bruises that are painful for a long period
• thinner skin or less flexibility in your skin
• brittle nails, or your nails breaking easily
• hair loss
Stem question: How much have you been affected by the following side-effects related to the use of your inhaler/s during the last 14 days?Respiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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6. Personality: Neuroticism scale of the Eysenck Personal-
ity Questionnaire Revised Short Scale (EPQ-RSS)[26]
scored 0–12; Negative affect scale of the Positive and Neg-
ative Affect Schedule (PANAS)[27] scored 10–50.
7. Patient demographics: age; gender; smoking status;
educational level.
All returned questionnaires were checked for missing
responses or inconsistencies, and queries were resolved
with the patient by telephone.
ICQ domain construction procedure and analysis
We chose initial factors with an eigenvalue of greater than
1 in principle component analysis which were above the
inflection point of the Cattell Scree plot [28]. Subse-
quently inter-item correlations of ≥0.50 were identified to
cluster remaining items.
ICQ endorsement and scaling procedure and analysis
The percentage of patients endorsing (scoring ≥1 on the
scale) each ICQ item and using each response option was
calculated.
Construct validity procedure
We used cross-sectional construct validity to test the valid-
ity of the ICQ. The construct validity method is applied
when developing a test of a construct ('construct' refers to
the measured characteristic – in this case perceived side
effect) for which no other measure exists. Construct valid-
ity can be undertaken by generating and empirically test-
ing a number of hypotheses, based on what is already
known about the construct [19]. We developed the fol-
lowing hypotheses based on their supporting rationales:
Rationale 1
The literature suggests that a dose-response can be
expected for side effects related to the use of ICS, with side
effects most likely to occur in higher doses [6].
Hypothesis 1
There is a hierarchical dose-response pattern for preva-
lence of the individual items on the ICQ and statistically
significant hierarchical differences in scores for each of the
15 domains – with the high ICS dose group scoring high-
est on the ICQ.
Rationale 2
A scale measuring current side effects of ICS should be
predicted by the current dose of ICS used. However, dis-
ease severity might also be associated with greater ICQ
scoring. Thus, in order to demonstrate that ICQ scores are
predicted by ICS dose, irrespective of severity, the ICQ
scores of patients with well-controlled (mild) disease
must still be independently associated with ICS dose.
Hypothesis 2
ICS dose independently predicts ICQ scoring after adjust-
ing for confounders, an association which remains in
patients with homogenous disease.
Rationale 3
Local side effects are caused by the action of steroid in the
oral-pharyngeal space, whereas systemic side effects occur
due to steroid absorbed into the systemic circulation.
These disparate mechanisms suggest stronger associations
among items in domains with a potentially homogeneous
route of action than those with a potentially heterogene-
ous route of action.
Hypothesis 3
There is greater convergence (that is, stronger association)
among items in ICQ domains caused by a potentially
homogenous route of action (e.g. the local side effect
domains 'Voice' and 'Oropharynx problems') than among
items in domains caused by heterogeneous routes (e.g.
'Oropharynx Problems' versus ICQ side effect domains
thought to be caused systemically e.g. 'Mood Problems'
and 'Skin, Hair and Nails' domains).
Construct validity analyses
Using univariate analyses, we explored differences in ICQ
scores between the four ICS dose groups (hypothesis 1).
We also explored differences in other study variables,
between the four ICS dose groups, in order to identify
potential confounding variables (p-values ≤ 0.10), along-
side those predicted by the research literature, for subse-
quent regression analysis (hypothesis 2). Non-normally
distributed variables were tested using appropriate non-
parametric tests, and for uniformity only the results of
non-parametric test are reported as parametric test results
were similar. Prevalence (scores > 0) of the 57 items on
the ICQ were plotted onto graphs to show the dose-
response pattern in reporting. Median (IQR) score and
prevalence (scores > 0) were also tabulated for the total
score and each domain of the ICQ. A multi-trait correla-
tion matrix of the domains of the ICQ was calculated to
determine the association among items in domains pre-
dicted to be caused via systemic or local routes of action
(hypothesis 3).
Linear regression analysis was carried out to determine the
extent to which the total ICQ score could be explained by
daily ICS dose after adjusting for potential confounders.
All variables were checked for normality prior to regres-
sion analysis. Given that ICQ scores were skewed with
many zero values we took natural logs of the total ICQ
score having initially added 0.5 to each score. This then
served as the dependent variable in a multivariate model.
In the regression model independent variables were ICS
dose group, ACQ score and variables for which potentialRespiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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confounding was indicated. ICS dose group and ACQ
score were first entered into the model followed by each
single independent confounder in order to establish
which variables showed independent associations with
ICQ score. Finally a stepwise procedure was employed
(following entry of ICS dose group and ACQ score) allow-
ing simultaneous entry of the independent confounders.
This analysis was subsequently repeated in those patients
with well-controlled asthma as determined by the ACQ
questionnaire (total ACQ score ≤ 0.75 [25]).
Reliability – reproducibility procedure and analysis
Test-retest reliability assesses the stability of a scale for
producing reproducible results over time. 76 randomly
selected construct validity patients, who were currently
using an ICS inhaler, completed a second questionnaire
after 7 days. The 7-day questionnaire included the ICQ
scale, the 6-item ACQ, questions on medication change in
the last 7 days, ICQ completion time (response options:
less than 10 minutes, 10–15 minutes; 16–20 minutes;
more than 20 minutes), missing side effects not included
in the scale and perceived difficulty of the ICQ scale
(response options: very difficult; difficult; not difficult;
easy; very easy). Excluded patients reported a change in
their ICS use or in any other medication from baseline
measurement. Intraclass correlation coefficients (ICC)
between baseline and follow-up ICQ scores were calcu-
lated to assess reproducibility.
Reliability – internal consistency procedure and analysis
Cronbach's alpha coefficient and item-total correlations
were calculated to test the internal consistency of the ICQ.
Study 2 – Responsiveness of the ICQ to changes in ICS use
Ethical approval for this study was obtained from Gram-
pian Research Ethics Committee. Dutch ethical approval
was sought but not required.
Patients
General Practitioners and Pulmonologists in North Neth-
erlands and Aberdeen Scotland, invited by letter, agreed to
recruit patients during any normal consultation which
resulted in starting, increasing or decreasing their patients
ICS dose by at least 400 µg. Patients were included in two
countries to improve recruitment numbers and provide a
representative sample of inhaler users. Physicians
informed the researchers of the patients' old and new ICS
prescriptions. Eligible patients were current inhaler users
with physician diagnosed asthma, who gave informed
consent, were aged ≥16 years, had not used oral steroids,
received no change in their ICS prescription for 3 months
prior to the study and received no further change during
the 6-months of the study (subsequent to the physician-
instigated dose change at study entry).
Responsiveness procedure
Participants completed a self-report questionnaire at base-
line and follow up (2- and 6-months after ICS change),
which measured: ICQ; 6-item ACQ (Forced expiratory
volume in one second, question omitted); Asthma Qual-
ity of Life Questionnaire (AQLQ(S)[29]; daily ICS use and
patient characteristics. We hypothesized that any change
in ICS dose (higher or lower), would be associated with a
reciprocal change in group side effect scores, for the total
and domain scores of the ICQ.
Responsiveness analysis
We compared differences in ICQ, ACQ and AQLQ(S)
scores at 2- and 6-months from baseline using the Wil-
coxon test. The ICQ scores of patients who received a
decrease in dose were reversed to analyze absolute change
from baseline at 2-months and 6-months in the whole
sample simultaneously. We produced a box plot of
change in total ICQ scores (the difference (delta, ∆)
between ICQ median total score at baseline and follow-
up) by ICS dose change group (increased ICS versus
decreased ICS). All statistical analyses in this article were
performed with SPSS version 11.0 (SPSS Inc., Chicago, IL,
U.S.A.).
Results
Study 1 – Domain construction, construct validity and 
reliability of the ICQ
Patients
Of 784 patients invited, 90% responded (n = 704). 318
were not eligible (no inhaler n = 239; oral or injected ster-
oid n = 44; ≥20 pack years n = 25; questionnaire returned
after closing date n = 8; questionnaire not filled in ade-
quately n = 2). 131 did not wish to participate, leaving
255 eligible patients for analysis (see Table 1 for patient
characteristics). The 131 non-participants were of similar
age (median (IQR) 38 (26–49)) and gender (49% male)
to the 255 participants included in the study (age 42 (33–
50); 44% male).
ICQ domain construction
Eight factors were identified using eigenvalues and the
Cattell Scree plot. Four items were constructed into 2
additional domains using inter-item correlations, leaving
the remaining 5 items to be formed into single item
domains. The final 14-day ICQ questionnaire therefore
consists of 15 domains (see Table 2).
ICQ scoring
The ICQ was scored on an item level from 0 (not at all) to
6 (a very great deal) other response options being: 1 (a
very little), 2 (a little), 3 (a moderate amount), 4 (quite a
lot), 5 (a great deal). In order that domain scores with dif-
fering numbers of items could be compared, the 15
domain scores were transformed into a score out of 100Respiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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((Raw domain score/(6 * no. items in domain)) *100).
The total score of the ICQ (0–100) was the average of the
15 domain scores (sum the scores of 15 domains/15). The
highest score represents the greatest side effect.
Endorsement and scaling
Endorsement frequency (i.e. the percentage of patients
scoring ≥1) for the 57 items in the ICQ scale ranged from
13% to 64%. Endorsement frequency was less than the
recommended 20% [18] for 4 items on the scale: 'oral
thrush' (13%), 'loss of ability to taste' (19%), 'a loss of
appetite' (15%) and 'swollen face or fluid around the face'
(15%). Notwithstanding this, we left the 4 items in, since
we recommend a less stringent approach to item endorse-
ment for a side effect scale where even low percentages of
reporting on the group level might be of significant clini-
cal importance. With respect to scaling (that is, the use of
each of the seven response options on the ICQ Likert scale
e.g. "not at all" to "a very great deal"), no single response
option for the ICQ scale was responded to by ≥95% of
participants.
Construct validity
A number of variables showed a linear relationship with
ICS dose group (Table 1); which may have confounded
scoring on the ICQ. These variables were age, asthma con-
trol, emergency GP appointments for asthma in last year,
educational level, number of daily puffs of SABA, daily
dose of LABA, courses of Prednisolone in the last 3 years,
number of concomitantly prescribed medications, nega-
tive affectivity score, and use of a spacer device. Variables
which showed no linear trend, but were potential con-
founders indicated by the research literature, were gender,
smoking status, use of nasal steroids, neuroticism score,
and mouth rinsing after inhalation. Age when asthma
diagnosed, number of comorbidities, and rhinitis diagno-
sis, were also assessed (data not shown) but were not sig-
nificantly different between groups.
Hypothesis 1
A dose-response was observed for all 57 items on the ICQ,
when comparing high- versus low-dose ICS groups (Fig-
ures 1 to 2). However the mid-dose group showed a lower
prevalence than the low-dose ICS group in the 'Unpleas-
ant Taste' domain (items 29, 30, 31, 38, 39), 'Oropharynx
Problems' domain (item 15) and the 'Taste Disruption'
domain (items 32, 33, 35). ICQ total and domain scores
showed hierarchical differences between dose groups
(with the highest scoring in the high dose ICS group) that
were statistically significant for 14 of the 15 domains
(Table 3). Only the 'Vision Deterioration' domain did not
reach statistical significance in this sample, although there
was a suggestion of an effect (p = 0.066).
Hypothesis 2
ICS dose group remained an independent predictor of
ICQ score (Table 4) in the stepwise linear regression anal-
yses, after adjusting for potential confounders: the
explained variance being 35.8%. Subsequent multiple
regression analysis in 124 patients with well-controlled
asthma (non ICS inhaler n = 9; low dose ICS n = 34; mid
dose n = 34; high dose n = 47), showed that only ICS dos-
age group (p < 0.001) and neuroticism score (p = 0.007)
were independent predictors of ICQ score (data not
shown).
Hypothesis 3
The multi-trait correlation matrix (Table 5) showed that
associations between items in side effect domains with a
potentially homogenous route of action were greater (r =
0.52; r = 0.39) than those between items in domains with
a potentially heterogeneous route (all ≤0.32).
Reliability – internal consistency
For the 57 items in the scale, all item-total correlations
were greater than r = 0.20 as recommended by Kline 1986
(in [18]). Cronbach's Alpha was 0.98, which was well
above the minimum (α = 0.70) recommended by Nun-
nally (1978) (in [18]) for internal consistency.
Reliability – reproducibility and patient acceptability
73 participants returned their second questionnaire. 68
patients had made no changes to their use of ICS or other
medication since baseline measurement. We had planned
to exclude patients if their ACQ score changed by more
than 0.5 from baseline (the scales minimal clinically
important difference [25]), but ICC for the whole sample
(n = 68) compared to those without a change in ACQ
score (n = 48) showed no detrimental impact upon the
reliability of the ICQ, so results for all 68 patients are
shown. ICC for 14 of the 15 domains were greater than
>0.5 as recommended for reproducibility coefficients [18]
(Table 6). Only the domain 'Facial Oedema' was slightly
less stable over 7 days (r = 0.41). The majority of patients
(88%) completed the questionnaire in less than 15 min-
utes, and 91% reported that the questionnaire was simple
to fill in. Four additional side effects were suggested, each
by one patient: pigment spots, fragile bones, itch in nose,
and problems with kidney and liver.
Study 2 – Responsiveness of the ICQ to changes in ICS use
Patients
82 General Practitioners volunteered to recruit patients
(67 North Netherlands (N), 15 Aberdeen, Scotland (S)),
but, after 1 year, practices produced low patient numbers
in both countries, predominantly due to low frequency of
ICS prescription change in general practice. We decided to
rationalize participating general practices to the 33 most
motivated (26 N, 7 S) and widened our recruitment net byRespiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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Prevalence of items in the 'Voice Problems', 'Unpleasant Taste' 'Oropharynx Problems' and 'Skin, Hair and Nails' domains of  the ICQ Figure 1
Prevalence of items in the 'Voice Problems', 'Unpleasant Taste' 'Oropharynx Problems' and 'Skin, Hair and 
Nails' domains of the ICQ. Square brackets indicate truncation of text – full item description in table 2
Non ICS inhaler
Low dose ICS
Mid dose ICS
High dose ICS
1. 
Hoarseness 
of the voice
2. A 'rough' 
voice
3. A 
noticeable 
change to 
your voice
4. [Your 
voice similar 
to 
recovering 
from flu]
5. [Your 
voice 'gone 
to back of 
throat']
6. Not being 
able to sing
7. [Loss of 
speech 
volume]
8. A feeling 
of 
exhaustion 
when talking
9. A painful 
throat when 
talking
10. [Others 
can't 
understand 
your 
speech]
11. A 
breaking 
voice
21. A 'rough' 
throat
22. A sore 
throat
23. An 
unpleasant 
feeling in 
your throat
24. A dry 
throat
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Prevalence of items in the 'Mood Problems', 'Taste Disruption', 'Perspiration', 'Oropharyngeal Itching', 'Thirst', 'Tiredness' and  five 1-item domains of the ICQ Figure 2
Prevalence of items in the 'Mood Problems', 'Taste Disruption', 'Perspiration', 'Oropharyngeal Itching', 
'Thirst', 'Tiredness' and five 1-item domains of the ICQ. Square brackets indicate truncation of text – full item descrip-
tion in table 2
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inviting an additional 6 secondary care physicians to
recruit patients in The Netherlands.
94 eligible patients were recruited at baseline (90 N; 4 S),
yet 16 deviated from prescribed ICS dose, 8 used oral ster-
oid, 5 dropped out (3 too busy, 1 illness, 1 stopped ICS
due to voice side effects), 3 were lost to follow up, and 1
could not complete the questionnaire. Thus we were able
to analyze data of 61 patients at 2-months (58 N; 3 S). We
could analyze 39 patients at 6 months, since a further 19
deviated from ICS dose change, 1 dropped out (illness)
and 2 used oral steroids (36 N; 3 S). Of the 39 participants
at 6-months, 21 patients (median age 50 (IQR 41, 65),
57% female, 91% mouth rinsing after inhalation, 57%
using budesonide) had received a median ICS dose
increase of 800 µg (IQR 400, 800), and 18 patients
(median age 57 (IQR 51, 63), 67% female, 100% mouth
rinsing after inhalation, 56% using budesonide) had
received a median ICS dose decrease of 450 µg (IQR -650,
-400).
Responsiveness
At 2-months from baseline, differences were seen in the
'Voice Problems' domain (p = 0.023). However, at 6
months from baseline the statistically significant differ-
ence in the domain 'Voice Problems' (p = 0.026)
remained and the domains 'Skin, Hair and Nails' (p =
0.064) and 'Facial Oedema' (p = 0.056) showed some evi-
dence of an effect (Table 7). Non-significant trends were
also observed for 'Perspiration' (p = 0.109), 'Unpleasant
Taste' (p = 0.155) and 'Dental Deterioration' (p = 0.185).
Scores for other domains showed less clear scoring trends
during the study. Total scores varied widely within groups,
but a trend was observed in ∆ ICQ total score (the differ-
ence (delta, ∆) between ICQ median total score at base-
line and 6-months measurements) relative to dose change
Table 4: Stepwise regression model of factors influencing ICQ total score
Model B-coefficient Standard error p-value
ACQ score 0.43 0.07 <0.001
Gender* -0.42 0.15 0.007
ICS dose group 0.37 0.07 <0.001
Neuroticism score 0.09 0.03 0.001
Number of concomitant medications used 0.21 0.10 0.038
*Female gender associated with higher side effect scoring
Dependent variable: logged ICQ total score
Table 3: Median score and prevalence by ICS dose group for ICQ total and 15 domains
ICQ Domain Non ICS Inhaler
n = 27
% >0 Low dose ICS
n = 61
% >0 Mid dose ICS
n = 62
% >0 High dose ICS
n = 105
% >0 p-value†
Total Score 5 (1–11) [89] 7 (3–14) [92] 10 (3–21) [92] 15 (9–30) [97] <0.001
Voice Problems 2 (0–8) [56] 3 (0–13) [70] 6 (0–22) [63] 13 (3–34) [79] <0.001
Oropharynx Problems 11 (0–19) [67] 9 (1–28) [75] 18 (3–41) [81] 20 (6–44) [86] 0.003
Unpleasant Taste 7 (0–24) [67] 5 (0–20) [61] 5 (0–19) [68] 10 (2–29) [77] 0.012
Skin, Hair and Nails 0 (0–14) [41] 5 (0–19) [57] 14 (0–24) [69] 19 (5–37) [81] <0.001
Mood Problems 0 (0–0) [11] 0 (0–19) [33] 0 (0–33) [46] 11 (0–39) [59] <0.001
Taste Disruption 0 (0–0) [11] 0 (0–0) [23] 0 (0–0) [16] 0 (0–14) [39] 0.001
Perspiration 0 (0–25) [30] 0 (0–33) [45] 0 (0–38) [46] 17 (0–42) [64] 0.002
Oropharyngeal Itching 0 (0–0) [15] 0 (0–8) [27] 0 (0–8) [32] 0 (0–25) [41] 0.002
Thirst 0 (0–25) [48] 8 (0–25) [55] 8 (0–35) [58] 25 (0–50) [72] <0.001
Tiredness 0 (0–13) [36] 8 (0–25) [51] 8 (0–33) [57] 25 (0–42) [74] <0.001
Oral Candidiasis 0 (0–0) [7] 0 (0–0) [8] 0 (0–0) [8] 0 (0–0) [20] 0.014
Facial Oedema 0 (0–0) [7] 0 (0–0) [7] 0 (0–0) [13] 0 (0–0) [22] 0.005
Vision Deterioration 0 (0–0) [19] 0 (0–17) [31] 0 (0–17) [33] 0 (0–33) [38] 0.066
Dental Deterioration 0 (0–0) [11] 0 (0–0) [15] 0 (0–13) [25] 0 (0–33) [40] <0.001
Eye Dryness 0 (0–17) [26] 0 (0–17) [28] 0 (0–17) [31] 0 (0–50) [50] 0.001
† Jonckheere-Terpstra Test
ICQ score median (IQR)
ICQ domain and total scores: 0 to 100
[% patients scoring % >0 within ICQ domain]Respiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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direction at 6-months (Figure 3), but not at 2-months
(data not shown).
At 6-months, asthma control and asthma-related quality
of life improved significantly from baseline in the group
whose ICS increased, but not for the group whose ICS
dose decreased (Table 8). Change at 2-months was similar
(data not shown).
Discussion
Medication-related side effects are of considerable con-
cern to patients and may result in their non-compliance to
prescribed regimens. Despite this, at the present time no
method exists for the systematic measurement of patients'
perceptions of inhaled corticosteroid side effects. Drug-
specific self-report questionnaires could provide a simple
method for communicating patients' side effect experi-
ences to their physician in everyday practice, during clini-
cal trials, and in new studies paramount for establishing
the impact of side effect on ICS adherence. In this paper,
using a combination of well-established methods, we first
constructed domains of the Inhaled Corticosteroid Ques-
tionnaire (ICQ) and then tested the validity, reliability
and initial responsiveness of the scale.
Study 1 – Construct validity and reliability
Our test of construct validity was based on a series of a pri-
ori set hypothesis which were all confirmed. A dose-
response was observed for reporting of all 57 items on the
scale and ICQ total and domain scores were statistically
significantly different between ICS dose groups. Of funda-
mental importance, scoring on the ICQ was predicted by
current daily ICS dose even after controlling for potential
confounding variables in regression analysis. Specifically,
this meant that after accounting for female gender,
asthma control, neuroticism and use of other medica-
tions, which also predicted higher scores, higher ICS dose
still independently and significantly predicted higher total
ICQ scores. Furthermore, associations among ICQ
domains supported the structural functioning of the scale.
Side effect domains of the ICQ thought to be caused by
the same pathway (action of glucocorticoids via oropha-
ryngeal deposition) such as 'Voice Problems' and
'Oropharynx Problems' were more highly correlated than
those thought to be caused via different routes of action,
such as 'Voice Problems' and 'Mood'(action of glucocorti-
coids via absorption into the systemic circulation). These
combined results show that the ICQ has good construct
validity.
A few construct validity results require further discussion.
The 'Vision Deterioration' domain of the ICQ showed evi-
dence of a dose effect, with prevalence in the high ICS
dose group (38%) double that of non ICS users (19%),
but overall differences between groups for this domain
did not reach statistical significance (p = 0.066). The clin-
ical importance of vision deterioration as a marker for
potential ICS-related glaucoma or cataract and the differ-
ences observed between ICS users and non-users support
its retention in the scale.
Higher neuroticism score consistently predicted higher
ICQ scoring in this sample providing further evidence for
the validity of the scale. Neuroticism is a personality factor
related to the propensity of experiencing emotional dis-
tress, poorer stress coping, higher ratings of poor health
[30] and increased reporting of symptoms [31,32]. It
therefore follows that persons high in neuroticism are also
likely to self-report greater side effects of medication, and
this is of considerable interest for future research.
It is possible that part of the dose-response observed in
ICQ scoring may reflect disease symptoms rather than
medication-related side effects. Because asthma patients
with worse symptoms generally have the worst asthma
control and are usually prescribed the highest ICS doses,
we presumed that asthma control would be related to ICQ
Table 6: ICC for 7 day test-retest of the ICQ
ICQ Domain No. of items in
domain
ICC % patients scoring zero
at baseline and follow-up
Total Score 0.91 6
Voice Problems 15 0.89 24
Oropharynx Problems 9 0.87 12
Unpleasant Taste 7 0.91 24
Skin, Hair and Nails 7 0.81 15
Mood Problems 3 0.73 41
Taste Disruption 3 0.80 56
Perspiration 2 0.75 35
Oropharyngeal Itching 2 0.83 61
Thirst 2 0.84 30
Tiredness 2 0.79 30
Oral Candidiasis 1 0.82 79
Facial Oedema 1 0.41 77
Vision Deterioration 1 0.80 55
Dental Deterioration 1 0.69 61
Eye Dryness 1 0.81 54
Table 5: A multi-trait correlation matrix to test convergence 
between the side effect domains of the ICQ
1234
1. Voice Problems (0.65)
2. Oropharynx Problems 0.52 (0.69)
3. Skin, Hair and Nails 0.27 0.28 (0.50)
4. Mood 0.32 0.32 0.39 (0.87)
R-values in bold show domains with a potentially homogenous route 
of action which should be higher than correlation coefficients in italics 
which show the heterogeneous domains tested. Remaining 
coefficients in brackets show the inter-item correlation for each 
domainRespiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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scoring. For this reason, we wished to test if the relation-
ship between ICS dose and ICQ still existed when asthma
control was no longer a predictor of ICQ scoring. Regres-
sion analysis in a subgroup of 124 patients with homoge-
nous asthma (ACQ score ≤ 0.75) showed that ICS dose
continued to explain the largest part of variation in ICQ
scoring after adjusting for potential confounders. Neurot-
icism also remained an important predictor. Together this
is suggestive evidence that the ICQ scale measures side
effects independently of disease control.
Our 7-day test re-test reliability data supports that the ICQ
is a reliable scale with good reproducibility over time.
However, the frequency of zero scoring at baseline and 7-
day follow-up may have augmented some reproducibility
coefficients. It is recommended that reproducibility coef-
ficients should be greater than 0.5 [18], and only one of
the 15 domains, i.e., 'Facial Oedema', was less stable over
7 days (r = 0.41). Without treatment, side effects can spon-
taneously resolve themselves during repeated measure-
ment. Facial oedema may be particularly vulnerable to
change over the relatively long re-test period of 7 days,
due to extraneous factors (such as allergy). Facial oedema
is however a recognized corticosteroid side effect and
since its validity was acceptable, the item is retained to
protect the content validity of the scale.
The ICQ showed excellent internal consistency in this
study (α = 0.98). This reliability coefficient is relatively
high, although not exceptional, as quality of life question-
naires often produce alphas of well above 0.9 (Airways
Questionnaire 20 [33]; St. George's Respiratory Question-
naire, Chronic Respiratory Disease Questionnaire [34]).
Side effect scales require good content validity (including
the range of potential side effects experienced), which can
simultaneously result in a lengthy scale and a relatively
high level of zero scoring which together inflate alpha
scores. The ICQ scale also shows appropriate item
endorsement (that is for every item on the scale ≥13% of
patients scored ≥1), and scale endorsement (that is, less
than 95% of patients used the same response option on
the ICQ's Likert scale e.g. "not at all" or "a very great
deal"). The ICQ was also acceptable to patients, com-
pleted without difficulty (91% of patients) in 15 minutes
or less (88% of patients), demonstrating the viability of
the scale for use in clinical practice or research.
Results should be considered in the context of our
research. All data in the study was necessarily self-reported
and the possibility of bias exists. We considered, but
finally rejected, the inclusion of an objective measure of
disease severity (e.g. lung function) in this study, since the
association between lung function and patients' self-
reported disease symptoms is rather tenuous [35-37], and
unlikely to provide information in addition to the Asthma
Control Questionnaire. Since our study population had
used ICS for a relatively long period (median (IQR): 11
(7–20) years), side effect reporting in this sample could
have become diminished due to habituation to side effect
over time, or conversely, augmented by an increased
awareness of side effect or the cumulative effect of long-
term ICS use. Our scale must necessarily measure the side
effect perceptions of patients, and the favorable validity
and reliability results we achieved in this sample,
Table 7: Change in ICQ score at 6-months for increased ICS and decreased ICS dose groups
ICQ score Increased ICS Dose (n = 21) Decreased ICS Dose (n = 18)
BL 6M BL 6M p-value*
Total Score 8 (3–26) 16 (7–24) 16 (8–28) 11 (5–31) 0.460
Voice Problems 8 (2–25)† 13 (4–37) 14 (6–36) 13 (2–22)† 0.026
Oropharynx Problems 24 (7–39) 30 (11–42) 29 (12–38) 13 (6–33) 0.330
Unpleasant Taste 5 (0–25) 17 (4–29) 8 (0–20) 5 (0–24) 0.155
Skin, Hair and Nails 7 (0–27) 14 (1–33) 23 (13–31) 11 (4–36) 0.064
Mood Problems 6 (0–31) 0 (0–22) 3 (0–33) 0 (0–19) 0.455
Taste Disruption 0 (0–28) 6 (0–17) 0 (0–18) 0 (0–17) 0.379
Perspiration 17 (0–42) 17 (0–42) 17 (0–38)† 17 (0–27) 0.109
Oropharyngeal Itching 0 (0–21) 0 (0–17) 0 (0–10) 0 (0–19) 0.533
Thirst 17 (0–50)† 25 (0–42) 17 (0–29) 13 (0–42) 0.593
Tiredness 17 (0–46) 25 (0–33) 33 (0–52) 29 (0–52) 0.465
Oral Candidiasis 0 (0–17) 0 (0–17) 0 (0–33) 0 (0–17) 0.403
Facial Oedema 0 (0–0) 0 (0–17) 0 (0–17) 0 (0–0) 0.056
Vision Deterioration 0 (0–33) 0 (0–33) 0 (0–33) 0 (0–17) 0.756
Dental Deterioration 0 (0–0) 0 (0–17)† 0 (0–17) 0 (0–0)† 0.185
Eye Dryness 0 (0–17) 0 (0–17) 33 (0–50) 17 (0–50) 0.915
* Wilcoxon test: p-values for change in absolute values of ICQ scores for all patients at 6M from BL
† data missing in domain for 1 patient
All data median (IQR)Respiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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strengthen our confidence in the scale. Our initial
response rate was very good (90%), which may reflect the
particularly compliant characteristics of our cohort
explaining, in part, their continued long-term use of ICS
regardless of the side effects they reported. For this reason
further validation work in different samples, in other dis-
eases for which ICS are prescribed, such as Chronic
Obstructive Pulmonary Disease, and in different countries
would be useful to add to our results.
Study 2 – Responsiveness of the ICQ to changes in ICS use
In our responsiveness study we compared ICQ scores at
baseline, to those at 2- and 6-months after a change in ICS
dose. The questionnaire showed potential evaluative
properties, especially for the domains 'Voice Problems' at
2- and 6-months and 'Skin, Hair and Nails' and 'Facial
Oedema' at 6-months. The difference in temporal respon-
siveness between these local and systemically caused side
effects seems consistent with differences in the emergence
of side effects on starting ICS: dysphonia can occur within
a few days, whereas skin atrophy can occur six weeks after
starting treatment [38,39].
Our results should be considered in the context and limi-
tation of the research design. Although we did not have
the opportunity to test the ICQ in a randomized control-
led design, which would have allowed us to rule out
regression to the mean or reporting bias, the fact that
trends in ICQ score change were largely reciprocal to dose
modulation and that change was stronger at 6- than at 2-
months, supports its potential evaluative properties. A
longer follow-up period may have been needed to allow
more time for side effects to respond to dose change, and
our observational design resulted in a high sample attri-
tion which occurred largely due to deviation from pre-
scribed ICS dose changes. This may explain our inability
to detect a statistically significant change in this study.
However this does not rule out potentially clinically
important change, since at 6-months the total ICQ score
showed a two-fold increase from baseline in the group
whose ICS dose had been increased. Moreover, it is
unlikely that modulation in asthma symptoms were
responsible for changes in side effect scores in this study,
since change in asthma control was not reciprocal to ICQ
scoring, in fact asthma control improved in the ICS
increasers group whose side effect 
worsened.
Temporal variation in the appearance of different side
effects [40] and differential responses to a change in dose
of medication (in number, duration or severity of side
effects) [5] in different individuals, can hamper respon-
siveness testing. One must take care not to over-interpret
Table 8: Change in asthma control and asthma quality of life scores at 6-months for increased ICS and decreased ICS dose groups
Scale Increased ICS Dose (n = 21) Decreased ICS Dose (n = 18)
BL 6M BL 6M
ACQ Total Score 1.5 (0.8, 2.3) 1.2 (0.7, 1.8)** 0.7 (0.3, 1.3) 0.8 (0.2, 1.4)
AQLQ(S) Total Score 5.1 (4.5, 5.9) 5.7 (5.1, 6.3)*† 6.0 (5.3, 6.6) 6.3 (5.5, 6.8)
All data median (IQR); ACQ (0–6) scored: 0 = best control, 6 = worst control; AQLQ(S) (7–1) scored: 7 = best, 1 = worst
Change from baseline tested with Wilcoxon *p = 0.001 ** p = 0.039
†Clinically important change (≥0.5 on scale)
Change in total ICQ score from baseline for Increased ICS  and Decreased ICS dose groups Figure 3
Change in total ICQ score from baseline for 
Increased ICS and Decreased ICS dose groups.Respiratory Research 2006, 7:131 http://respiratory-research.com/content/7/1/131
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results before a large number of tests have been under-
taken. Additional assessment, ideally in a randomized
controlled trial, must be carried out to confirm the
responsiveness of the ICQ.
Conclusion
We have developed the Inhaled Corticosteroid Question-
naire; a useful new tool for measuring patients' percep-
tions of ICS associated side effects. The ICQ shows good
reliability and validity in asthma patients and has good
discriminative properties. It also has potential evaluative
properties that require further testing. Used for systematic
measurement, this simple questionnaire may provide a
greater understanding of the side effect perceptions of
patients in clinical practice and clinical trials, and will
yield useful new perspectives on the relationship between
perceived side effect of ICS and adherence.
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